Safety of in utero exposure to maternal IBD pharmacotherapies
Nat Rev Gastroenterol Hepatol
.
2022 Apr;19(4):213-214.
doi: 10.1038/s41575-021-00572-9.
Authors
Ralley E Prentice
1
2
3
4
,
Sally J Bell
1
2
,
Claudia A Nold-Petry
4
5
,
Marcel F Nold
4
5
6
,
Rimma Goldberg
7
8
9
Affiliations
1
Gastroenterology Department, Monash Health, Melbourne, Victoria, Australia.
2
School of Clinical Sciences, Department of Medicine, Monash University, Melbourne, Victoria, Australia.
3
St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.
4
Ritchie Centre, Hudson Institute of Medical Research, Melbourne, Victoria, Australia.
5
Department of Paediatrics, Monash University, Melbourne, Victoria, Australia.
6
Monash Newborn, Monash Children's Hospital, Melbourne, Victoria, Australia.
7
Gastroenterology Department, Monash Health, Melbourne, Victoria, Australia. rimma.goldberg@monash.edu.
8
School of Clinical Sciences, Department of Medicine, Monash University, Melbourne, Victoria, Australia. rimma.goldberg@monash.edu.
9
Ritchie Centre, Hudson Institute of Medical Research, Melbourne, Victoria, Australia. rimma.goldberg@monash.edu.
PMID:
34987229
DOI:
10.1038/s41575-021-00572-9
No abstract available
Publication types
Research Support, Non-U.S. Gov't
MeSH terms
Humans
Inflammatory Bowel Diseases* / drug therapy
Prenatal Exposure Delayed Effects*